Advertisement

Organisation › Details
Nosopharm SAS
Nosopharm is a biotechnology company specialized in the research and development of new antimicrobial molecules. Nosopharm discovered and developed NOSO-502, a first-in-class antibiotic for the treatment of multidrug-resistant hospital-acquired infections. It has developed a unique expertise in the discovery of natural bioactive products stemming from the Xenorhadbus and Photorhabdus microbial genera and in the medicinal chemistry of Odilorhabdins, the new class of antibiotics to which NOSO-502 belongs. Founded in 2009, Nosopharm is based in Lyon, France, and has a staff of eight. To date, the company has raised a total of €4.3M ($5.2M) in private equity and received €3.8M ($4.6M) in grants from Bpifrance, IMI, DGA, Region Languedoc-Roussillon and FEDER. *
![]() |
Start | 2009-02-01 established |
![]() |
Industry | anti-infective drug |
Industry 2 | antibiotic | |
![]() |
Person | Villain-Guillot, Philippe (Nosopharm 201703 President) |
![]() |
Region | Lyon |
Country | France | |
Street | 21 avenue Georges Pompidou | |
City | 69486 Lyon Cedex 3 | |
Tel | +33-4-1171-6185 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | A: 1 to 10 (2018-02-12) |
* Document for »About Section«: | ||
Record changed: 2024-03-30 |
Advertisement

More documents for Nosopharm SAS
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top